CELCUITY INC

CELC14 Dec 2024
Healthcare
$12.56
-0.01 (-0.71%)
Lowest Today
$12.28
Highest Today
$12.76
Today’s Open
$12.56
Prev. Close
$12.61
52 Week High
$22.19
52 Week Low
$11.51
To Invest in CELCUITY INC

CELCUITY INC

Healthcare
CELC14 Dec 2024
-0.01 (-0.71%)
1M
3M
6M
1Y
5Y
Low
$12.28
Day’s Range
High
$12.76
12.28
52 Week Low
$11.51
52-Week Range
52 Week High
$22.19
11.51
1 Day
-
1 Week
-3.43%
1 month return
-11.26%
3 month return
-17.46%
6 month return
-16.81%
1 Year return
-15.31%
3 Years return
+3.98%
5 Years return
+32.06%
10 Years return
-
Institutional Holdings
Bvf Inc
9.33
Perceptive Advisors LLC
6.36
Baker Bros Advisors LP
5.05
Vanguard Group Inc
4.38
Eventide Asset Management, LLC
4.13
Eventide Healthcare & Life Sciences I
4.13
COMMODORE CAPITAL LP
4.1

Market Status

Fundamentals
Market Cap
477.11 mln
PB Ratio
3.13
PE Ratio
0
Enterprise Value
310.25 mln
Total Assets
191.22 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Organisation
CELCUITY INC
Employees
55
Industry
Biotechnology
CEO
Mr. Brian F. Sullivan
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step